Is tucatinib/tucatinib already on the market in China?

Tucatinib/Tucatinib (Tucatinib) has not yet been officially launched in China. This situation makes it challenging for many patients who require treatment with this drug. Globally, tucatinib has been approved by regulatory agencies in many countries and regions, especially in the U.S. and European markets, and its efficacy and safety have been widely recognized.

Tucatinib is a targeted therapy for HER2-positive breast cancer, especially for patients whose disease has progressed after multiple treatments. Its mechanism is to slow down or prevent the growth of tumor cells by selectively inhibiting the tyrosine kinase activity of the HER2 receptor. In some clinical trials, tucatinib combined with trastuzumab has shown a significant improvement in progression-free survival (PFS), providing a new treatment option for patients with HER2-positive metastatic breast cancer.

Although tucatinib is recognized and widely used internationally, in China, because it has not yet been approved for marketing, patients cannot purchase the drug through formal channels, and medical insurance cannot cover the cost. This has brought considerable financial pressure and psychological burden to many patients who need this drug. The high price of original drugs and the lack of alternative treatment options put many patients in a difficult situation.

At the same time, with the development of the pharmaceutical industry, generic drugs of tucatinib have appeared abroad. These generic drugs are similar to the original drug in terms of ingredients and efficacy, and their prices have been significantly reduced, allowing some patients to obtain similar therapeutic effects at a lower cost. However, there is still some uncertainty about the legality and availability of generic drugs in the Chinese market. Patients must be cautious when using them and ensure that the sources are reliable.

Reference materials:https://www.tukysa.com/